About Springworks therapeutics
Springworks Therapeutics: Pioneering Cancer Breakthroughs with Passion and Urgency
Springworks Therapeutics is a biopharmaceutical company that is dedicated to discovering and developing innovative therapies for patients with severe diseases, particularly cancer. The company was founded in 2017 by a team of experienced scientists, clinicians, and business leaders who shared a common vision of transforming the lives of patients through cutting-edge research and development.
At Springworks Therapeutics, we believe that every patient deserves access to safe, effective, and affordable treatments that can improve their quality of life. We are committed to advancing the frontiers of science by exploring new pathways for drug discovery and development. Our approach is based on collaboration, innovation, and agility – we work closely with academic institutions, industry partners, regulatory agencies, patient advocacy groups, and other stakeholders to accelerate the translation of scientific discoveries into clinical practice.
Our mission is simple but ambitious: we want to create new cancer breakthroughs that can make a real difference in people's lives. To achieve this goal, we have assembled a world-class team of experts who bring diverse perspectives and skills to our organization. Our team includes scientists with expertise in oncology biology; clinicians with experience in designing clinical trials; regulatory affairs professionals who understand the complex landscape of drug development; business leaders who know how to navigate the competitive market; and patient advocates who provide valuable insights into the needs and preferences of patients.
One key area where Springworks Therapeutics has made significant progress is in developing targeted therapies for rare cancers. These are cancers that affect fewer than 200 thousand people per year in the United States but can be devastating for those affected by them. By focusing on these underserved areas of unmet medical need, we hope to make a meaningful impact on patients' lives while also creating value for our shareholders.
Our lead product candidate is nirogacestat (formerly PF-03084014), an oral small molecule gamma secretase inhibitor being developed as monotherapy or combination therapy for desmoid tumors (DT) / aggressive fibromatosis (AF). Nirogacestat has been granted Orphan Drug Designation by both FDA & EMA as well as Fast Track designation from FDA based on early data from Phase 1b/2 study which demonstrated promising efficacy signals along with manageable safety profile across multiple tumor types including DT/AF.
In addition to nirogacestat program ,we have several other programs underway targeting various solid tumors including KRAS G12C mutant NSCLC , HER2+ breast cancer , RET fusion positive solid tumors etc . We are also exploring novel targets such as SHP2 inhibition which has potential application across multiple tumor types .
At Springworks Therapeutics ,we believe our success depends not only on what we do but how we do it .We strive hard everyday towards building an inclusive culture where everyone feels valued,respected & empowered .We take pride in our core values - Think Hard,Care Hard & Act With Urgency - which guide us through every decision making process .
In conclusion,Springworks therapeutics stands at forefront when it comes down towards developing innovative therapies targeting severe diseases like cancer .With its strong pipeline comprising both targeted small molecules & biologics alongwith its passionate workforce driven towards making difference ,the company looks poised towards achieving its mission statement "To relentlessly pursue every possibility until there's nothing left between hopelessness & hope".